Lead
On March 11, 2026, the Baltimore Ravens withdrew from a proposed trade to acquire Pro Bowl defensive end Maxx Crosby from the Las Vegas Raiders, the Raiders confirmed. Ravens general manager Eric DeCosta said the team had been enthusiastic about adding Crosby but could not complete the normal acquisition process after reviewing information gathered during the pre-trade period. The decision returns the Ravens’ 2026 and 2027 first-round picks to Baltimore and ends what had been reported as a high-profile swap. Both organizations and Crosby’s representatives described the outcome as difficult for the player and the clubs involved.
Key Takeaways
- The Ravens announced March 11, 2026, that they backed out of a trade to acquire Maxx Crosby from the Raiders, rescinding a previously agreed framework.
- Ravens GM Eric DeCosta said the team could not complete its internal evaluation process and called the decision a “tough call” for the organization.
- Reported terms that had been discussed included two first-round picks from the Ravens for Crosby; those 2026 and 2027 first-round selections remain with Baltimore.
- NFL Network reporter Mike Garafolo has attributed the collapsed deal to a medical issue; that explanation has not been independently confirmed by the Ravens in full detail.
- Crosby, 28, has played through a knee injury during parts of the 2025 season; his agent C.J. Laboy tweeted that Crosby’s surgeon, Dr. Neal ElAttrache, says recovery is on schedule.
- The Ravens signed Trey Hendrickson the same week; DeCosta said the Hendrickson move was separate and not the decisive factor in backing out.
- DeCosta expressed regret and sensitivity about informing Crosby and emphasized the organization’s responsibility to fans, ownership and the long-term health of the roster.
Background
The trade talks unfolded over several days near the opening of the NFL league year, a period when teams finalize free-agent moves and trades. Baltimore reportedly negotiated with Las Vegas on terms that industry outlets described as involving two first-round picks. Trades are not official until the start of the new league year, leaving room for additional review steps including medicals and internal vetting.
Maxx Crosby, 28, has been one of the league’s most productive edge rushers over the past seven seasons and was widely reported as the centerpiece of the potential deal. The Ravens, meanwhile, are operating with a plan to upgrade their pass rush and manage salary-cap and roster-building choices; the franchise also restructured contracts and signed free agents during the same window.
Main Event
DeCosta said the Ravens had spent significant time in Florida meeting with decision-makers and that initial discussions suggested traction on adding Crosby. He described a standard trade process that includes bringing a player in for information-gathering and vetting; according to DeCosta, the organization could not complete those steps to its satisfaction and therefore elected to withdraw.
The Raiders issued a brief statement confirming Baltimore backed out and declined further comment. Industry reporters immediately flagged a medical reason as the likely cause; DeCosta stopped short of detailing specific medical findings but emphasized the organization’s duty to act on information it deems material.
Within hours of the trade news, Crosby’s camp posted a statement saying the player is progressing in recovery and that surgeon Dr. Neal ElAttrache considers him on schedule to return in the offseason program. The conflicting public signals—media reports citing medical concerns and the agent’s optimistic update—left the core reason for the reversal characterized publicly as unresolved.
With the deal undone, Baltimore retains its first-round choices for 2026 and 2027 and has reversed any draft-board alterations made during negotiations. DeCosta said the team will pivot to a mix of free agency, the draft (the Ravens hold 11 picks in 2026), and targeted signings to address roster needs.
Analysis & Implications
The canceled transaction has several immediate effects. First, Baltimore preserves two valuable first-round picks, which restores draft capital that can be used to add young contributors or packaged in a future trade. That outcome reduces near-term risk for the Ravens but also leaves the pass-rush upgrade unresolved at least for now.
Second, the episode underlines how pre-trade medical and evaluative processes can override negotiated agreements before they become official. In modern NFL deals, conditional terms, medical reviews and additional diagnostics routinely affect a team’s willingness to finalize a trade when long-term availability or recovery timetables are in question.
Third, the public disagreement between media reports (medical concern) and the player’s representatives (surgeon optimistic) illustrates a communications gap that can complicate roster planning and public perception. For the Raiders, the reversal is also disruptive: they lose a concluded trade framework and must now re-evaluate how to monetize or retain an in-place starter.
Longer-term, the incident could affect future negotiation dynamics. Other teams and agents will note Baltimore’s insistence on comprehensive vetting; the Ravens’ stance may be viewed as conservative stewardship or, to some observers, a painful missed opportunity depending on how Crosby’s recovery progresses and how the 2026–27 draft classes develop.
Comparison & Data
| Year | Draft Pick | Reported Status |
|---|---|---|
| 2026 | First-round pick | Retained by Ravens |
| 2027 | First-round pick | Retained by Ravens |
Restoring two first-round selections keeps Baltimore among the more asset-rich clubs entering the 2026 draft cycle. The Ravens’ front office has historically leveraged multiple draft picks and targeted free-agent investments; having these picks back increases flexibility for both immediate roster building and future strategic trades.
Reactions & Quotes
Ravens management framed the decision as difficult but necessary.
“We were really excited about adding Max… we were not able to complete the process of acquiring the player based on our assessment.”
Eric DeCosta, Ravens GM (paraphrased)
DeCosta said he felt personally affected by informing Crosby and acknowledged fan disappointment.
“I know our fans are upset, devastated. I understand that.”
Eric DeCosta (paraphrased)
Crosby’s agent offered a conflicting public read on recovery timelines.
“Maxx continues to be on track in his recovery… and will undoubtedly return as the dominant game wrecker he has been these past 7 seasons.”
C.J. Laboy, agent for Maxx Crosby (agent statement on X)
Unconfirmed
- Reports attributing the reversal specifically to a medical finding remain unconfirmed by a fully detailed, public disclosure from the Ravens; the team cited an inability to complete its internal assessment.
- Crosby’s recovery timeline is described by his agent and surgeon as on schedule; independent confirmation of those clinical details has not been published.
- Any specific medical test or evaluation that directly caused the Ravens to withdraw has not been publicly named by Baltimore.
Bottom Line
The Ravens’ decision to back out of the Maxx Crosby trade reasserts internal vetting as a decisive factor in trades that have only been agreed in principle. Baltimore keeps two first-round picks and will redirect resources to free agency and the 2026 draft, while the immediate pass-rush upgrade goal remains open.
For Maxx Crosby and the Raiders, public statements paint a picture of competing narratives—media reports citing medical concerns and the player’s camp signaling an on-schedule recovery. The coming weeks will likely clarify whether the reversal was primarily medical, procedural or a combination of evaluative judgments; that clarity will shape how fans and rival teams judge both franchises’ actions.
Sources
- WBAL-TV (local news report and interview excerpts with Ravens GM Eric DeCosta)
- ESPN (national sports media reporting on reported trade terms and league coverage)
- NFL Network (league media reporting, including medical-report attribution)